Patent describing the effects of Nano policosanol as a VEGF promoter that could find use in therapeutic angiogenesis. Other biomarkers like Adiponectin increase that could find use in obesity. The patent also shows that Policosanol Nano is a DPP IV agonist and could be useful in Cancer. Patent also describes its use in reducing sugar and interestingly it increases DPP-IV which is the anti thesis of DPP IV products in the market. this will find use in diabetic foot ulcers where Glucose needs to be controlled before blood vessels can grow. Since Octacosanol increases VEGF this will be useful in people with diabetic foot ulcers and also ischemic heart disease. Also it could be useful in Hyeprlipidemia and affects lipid profile as well In addition it has powerful effect on reducing triglycerides and also reducing glucose and reducing Hba1C. This and previous patent are available for licensing.
Patent describing the effects of Nano policosanol as a VEGF promoter that could find use in therapeutic angiogenesis. Other biomarkers like Adiponectin increase that could find use in obesity. The patent also shows that Policosanol Nano is a DPP IV agonist and could be useful in Cancer. Patent also describes its use in reducing sugar and interestingly it increases DPP-IV which is the anti thesis of DPP IV products in the market. this will find use in diabetic foot ulcers where Glucose needs to be controlled before blood vessels can grow. Since Octacosanol increases VEGF this will be useful in people with diabetic foot ulcers and also ischemic heart disease. Also it could be useful in Hyeprlipidemia and affects lipid profile as well In addition it has powerful effect on reducing triglycerides and also reducing glucose and reducing Hba1C. This and previous patent are available for licensing.
Patent describing the effects of Nano policosanol as a VEGF promoter that could find use in therapeutic angiogenesis. Other biomarkers like Adiponectin increase that could find use in obesity. The patent also shows that Policosanol Nano is a DPP IV agonist and could be useful in Cancer. Patent also describes its use in reducing sugar and interestingly it increases DPP-IV which is the anti thesis of DPP IV products in the market. this will find use in diabetic foot ulcers where Glucose needs to be controlled before blood vessels can grow. Since Octacosanol increases VEGF this will be useful in people with diabetic foot ulcers and also ischemic heart disease. Also it could be useful in Hyeprlipidemia and affects lipid profile as well In addition it has powerful effect on reducing triglycerides and also reducing glucose and reducing Hba1C. This and previous patent are available for licensing.